01—Abstract
Summary
Summary of the 10-K filed February 15, 2024. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals' FY2023 10-K shows a company whose financial profile is dominated by its cystic fibrosis franchise.
Net product revenues rose 11% to $9.87 billiona, driven by strong ex-U.S. uptake and label expansions of TRIKAFTA/KAFTRIO, with TRIKAFTA/KAFTRIO alone generating $8.94 billion (up 16%). Income from operations fell 11% to $3.83 billion because operating expenses rose 31% to $6.04 billion, reflecting higher R&D, $527 million of acquired in-process R&D, and pre-launch SG&A. Net income grew 9% to $3.62 billion, or $13.89 per diluted share, helped by a $548 million swing to other non-operating income driven mainly by interest income of $615 million.
The effective tax rate fell to 17.4% from 21.5%, though cash taxes paid rose sharply to $1.68 billionb. Operating cash flow declined to $3.54 billion from $4.13 billion, and total cash and marketable securities reached $13.7 billion. The filing's key forward-looking catalysts are the planned mid-2024 global filings for the once-daily triple combination vanzacaftor/tezacaftor/deutivacaftor and the planned mid-2024 NDA for the non-opioid pain candidate VX-548, plus the CASGEVY launch for sickle cell disease and beta thalassemia, which is expected to be a foundational but early-revenue year.
Risks include heavy concentration in CF revenue, the Inflation Reduction Act and state drug-pricing pressure, the pause of the VX-880 type 1 diabetes trial after two patient deaths, and pending patent litigation over KALYDECO generics, with several settlements already reached. For investors, the central question is whether the CF franchise can keep compounding while the company funds a large, costly pipeline and multiple first-time launches. The company has ample liquidity to self-fund these efforts and continued share repurchases under a $3.0 billionc program, with $2.6 billion remaining.
02—Key points
Key Highlights
- Net product revenues rose 11% to $9.87 billion in 2023, led by TRIKAFTA/KAFTRIO, which grew 16% to $8.94 billion; ex-U.S. revenues grew 18% to $3.83 billion.
- Income from operations declined 11% to $3.83 billion as operating costs rose 31% to $6.04 billion, including R&D up 25% to $3.16 billion and acquired in-process R&D of $527.1 million.
- Net income increased 9% to $3.62 billion, or $13.89 per diluted share, supported by $614.7 million of interest income and an effective tax rate of 17.4% (vs. 21.5% in 2022).
- Cash, cash equivalents and marketable securities increased to $13.7 billion; operating cash flow fell to $3.54 billion as cash taxes paid rose to $1.68 billion.
- CASGEVY, the first CRISPR-based therapy, was approved in the U.S., E.U., U.K., Saudi Arabia and Bahrain for SCD and TDT; management expects 2024 to be a foundational launch year with first patients beginning a multi-month treatment.
- Near-term catalysts include global filings for vanzacaftor/tezacaftor/deutivacaftor and an NDA for VX-548 in acute pain, both targeted for mid-2024, plus a planned Phase 3 program for VX-548 in diabetic peripheral neuropathy.
- Key risks include CF revenue concentration (substantially all product revenue), IRA and state drug-pricing pressure, the protocol-specified pause of the VX-880 type 1 diabetes trial after two patient deaths, and ongoing KALYDECO generic patent litigation.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2023, Vertex Pharmaceuticals Inc kept $0.37.
- Revenue$9.87B100.0%
- Cost of revenue−$1.26B12.8%
- Gross profit$8.61B87.2%
- Operating costs−$4.78B48.4%
- Operating income$3.83B38.8%
- Interest, other & tax−$212.4M2.2%
- Net income$3.62B36.7%
Where FY2023 revenue went
$9.87B- Other operating costs: $3.64B, 37% of revenue
- Net income: $3.62B, 37% of revenue
- Cost of revenue: $1.26B, 13% of revenue
- SG&A: $1.14B, 12% of revenue
- Interest, other & tax: $212.4M, 2.2% of revenue
Kept 37% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 15, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $9.87B$8.93B | +10.5% |
| Cost of Revenue | $1.26B$1.08B | +16.8% |
| Gross Profit | $8.61B$7.85B | +9.6% |
| SG&A Expenses | $1.14B$944.70M | +20.3% |
| Operating Expenses | $6.04B$4.62B | +30.6% |
| Operating Income | $3.83B$4.31B | −11.0% |
| Net Income | $3.62B$3.32B | +9.0% |
| EPS (Basic) | $14.05$12.97 | +8.3% |
| EPS (Diluted) | $13.89$12.82 | +8.3% |
| Shares Outstanding (Basic) | 257.70M256.10M | +0.6% |
| Shares Outstanding (Diluted) | 260.50M259.10M | +0.5% |
05—Questions
Frequently Asked Questions
What drove Vertex's revenue growth in 2023?
Revenue growth was driven primarily by continued strong uptake of TRIKAFTA/KAFTRIO in ex-U.S. markets, label extensions into younger age groups (including children aged 2 to 5), and continued U.S. TRIKAFTA performance. Revenue from the company's other CF medicines declined as patients switched to TRIKAFTA/KAFTRIO.
Why did operating income fall even though revenue grew?
Operating expenses rose 31%, to $6.04 billion. The increase reflected higher R&D spending on mid- to late-stage programs, $527.1 million of acquired in-process R&D (including $225.1 million upfront to Entrada and $170 million to CRISPR for T1D), and SG&A increases to prepare for the VX-548 and CASGEVY launches.
How concentrated is Vertex's business, and what are the main risks?
Substantially all product revenue comes from CF medicines, so the company is highly dependent on that franchise. Other risks include U.S. drug-pricing reforms such as the IRA and state prescription drug affordability boards, reimbursement challenges outside the U.S., the paused VX-880 type 1 diabetes trial after two patient deaths, and patent litigation over generic KALYDECO, where several challengers have settled.
What are the key pipeline and launch catalysts for 2024?
The company plans to submit global regulatory filings for the once-daily triple combination vanzacaftor/tezacaftor/deutivacaftor by mid-2024, including an FDA NDA using a priority review voucher. It also plans an NDA for VX-548 in moderate-to-severe acute pain by mid-2024, advance VX-548 into pivotal development in diabetic peripheral neuropathy, and begin a Phase 3 inaxaplin program in APOL1-mediated kidney disease in Q1 2024. VX-522 data is expected in late 2024 or early 2025.
Is Vertex's balance sheet able to fund its investment program?
Yes. Vertex held $13.7 billion in cash, cash equivalents and marketable securities at year-end 2023, and management says existing cash plus product cash flow is sufficient for at least the next twelve months. The company also has an undrawn $500 million revolving credit facility and $2.6 billion remaining under its $3.0 billion share repurchase program.
06—Continue